Subject Index

Italic page numbers indicate figures; page number followed by “t” indicate tables.

A

Accreditation Council for Continuing Medical Education (ACCME), 7
Accreditation Council for Graduate Medical Education, 45, 66, 67
Acromegaly, 18, 21
Activa RC, 11
Active learning, process of, 57
Acyclovir, for cold sores, 74
Adaptive trial designs, 38–39
Advocacy, for health policy, 71
“Aequnimitas” (Osler), 7
All-or-none diseases, 54
Ambulatory Care Quality Alliance, 47
American Association of Neurological Surgeons (AANS), 46, 66
American Association of Retired Persons (AARP), 47
American Board of Medical Specialties (ABMS), 7, 45, 66, 67
American Board of Neurological Surgery (ABNS), 45, 68
American Board of Pediatric Neurological Surgery, 67
American Medical Association (AMA), 46
L-Amino acid decarboxylase, 14
5-Aminolevulenic acid (ALA), 93–97, 95
Amyotropic lateral sclerosis (ALS), 132
Anaplastic astrocytoma (AA), 95, 99
Anaplastic mixed oligodendroglioma, 99
Anaplastic oligodendroglioma, 99
Anecdotal experience, as evidence, 25
Animal models
Drosophila, neuromodulation studies, 14
mouse
of intracerebral tumors, 102–105, 103, 104
of spinal cord contusion, 85
U87 cell xenografts, 111, 114
rat, for ALS, 132
Annual meetings, learning through, 5
Anorexia, DBS for, 9
Anticonvulsant therapy, 74
Arcadis Orbic system, 21
Arteriovenous malformations (AVMs)
classification of, 41
distribution of patients based on, 42t
grade I, 41
grade II, 41
grade III, 41–44
grade IIIA, 42
grade IIIB, 42
grade IIIC, 43
grade IV, 43
grade V, 43, 43–44
outcomes and, 41–44
surgical results, 42t, 43t
treatment strategies and, 41t
diagnosis, 41
exposure of, 41
microsurgical resection in, 40
MRI imaging of surgical outcomes, 42t
patient selection, 40–41
residual, 44
saccular aneurysms associated with, 41
supratentorial, 40–44
treatment, 40, 44
Asher, Anthony, 49, 53
Assessments, instructional methodology studies, 59
Astrocytomas, IHC staining, 99
Autonomic function assessment, 86, 88–89, 89, 90
Autonomy
of patients, 35t
principle of, 34
B

Bacterial artificial chromosome (BAC) expressing green fluorescent protein, 125
Hb9::GFP transfection, 125, 131
transfection protocol, 127
Bacterial artificial chromosome—transgenic hESC cell line characterization of, 126, 128
differentiation to motor neuron lineage, 128
electrophysical analysis, 127
immunofluorescence studies, 127
microscopy studies, 127
PCR analysis, 127, 130
results, 127–130
transcriptome analysis, 127
Balloon compression, injury caused by, 73–74
Barkan, Ariel, 18
Basso, Beattie, Bresnahn locomotor scale, 87–88, 87t, 88
Basso Mouse scale (BMS), 86, 87–88, 87t, 89
Bayesian trial designs, 38–39
B16EGFRvIII cells, 102, 103, 103t, 104
effect on U87 cell xenografts, 114, 115
Beliefs, knowledge and, 59
Belmont report, 34
Beneficence, principle of, 34, 35t
Benzel. E.C., 49–53
Biases
core ideologies and, 50–51
forms of, 51
risk in meta-analyses, 29
in study design, 27
unpredictability paradox and, 27
Bipolar cauterization, 41
Bleeding, control of, 41
Blinding
definition, 27
in surgical RCTs, 28
Bortezomib (Velcade)
cell culture studies, 108, 109
cell fate after TMZ and, 113–114
delayed treatment with, 113–114
effect on U87 cell xenografts, 114, 115

134
growth arrest study, 110
sensitizing effect of, 116–117
TMZ treatment with, 113
Bosk, Charles, 35
Bovie devices, 20
Bradydactyia, trigeminal nerve compression and, 74
Bread mold colony, 50
Bridges to Excellence, 46
Built to Last (Collins and Porras), 51

C

Cabergoline, 21
α-CamKII promoter, 15
Cannabinoid CB₁ receptor
function of, 84–85
inhibition of, 84–92
localization of, 84
mechanism of action, 84
Cannabinoid CB₂ receptor
activation of, 84–92, 85
localization of, 85
mechanism of action, 84
Cannabinoids
clinical applications for, 84
terminology, 84
Cannabis sativa, 84
Carbamazepine, 74
Case reports, as evidence, 24–25
Case series
as evidence, 24–25
with external controls, 25–27
with internal controls, 25–27
uncontrolled, 24–25
Catheters, antibiotic-impregnated, 11
CD8, IHC staining, 99
Census sessions, 5
Central Brain Tumor Registry, 18
Cerebral hemorrhage, intraparenchymal, 44
Cerebrospinal fluid (cSF) leakage, 20
Cervical cordotomy, percutaneous, 73
Chain, Ernst Boris, 50
Chandler, W.F., 2
Channelrhodopsin-2 gene (ChR2), 14, 15
Chromophores, 14
Chronic pain, DBS for, 9
C25II sonic hedgehog, 126, 128
Clindamycin/rifampin, catheters impregnated with, 11
Clinical research
concept of equipoise, 35–36
ethical foundation of, 34
ethical principles of, 35
future of, 37–39
protection of human subjects, 35
Clinical trials
ethical challenges to, 35, 36
neurosurgical, 36
phase II, 25
phase III, 25
frequentist design, 38
future beyond, 37–39
prospective designs, 38
surgical, 35
Clinical wisdom
concept of, 49
in daily practice, 51
definition of, 53
foundation of, 49
precedence of, 52–53
teaching of, 51–52
Clinician-learners, characteristics of, 5
Commercialism, medicine and, 70
Competency, measurement of, 4
Computed tomography (CT)
of arteriovenous malformations, 41
diagnostic, 41
visibility of vitamin E capsules, 82
Concepts, knowledge and, 59
Confidence intervals, heterogeneity and, 29
Conflict-of-interest issues, 51
Confounding by indication, 25
Congress of Neurological Surgeons, 46, 66
Congressional Budget Office, 70, 71
Continuing medical education
continuing development of, 7
licensure and, 45–46
Continuous performance assessments, 5
Control populations
for clinical trials, 37
historical, 26
instructional methodology studies, 59
selection of, 26
Copper sulfate, for fiducials, 80, 83
Core ideologies, biases and, 50–51
Corticotropin, elevated, 19
Cortisol
serum levels, 19
urinary free, 19
 Craniootomy, size of, 41
Creativity
clinical wisdom and, 49–50
core ideologies and, 52
decision making and, 50
Credé maneuver, 86
Crossing the Quality Chasm (IOM), 46
Cushing, Harvey, 70
Cushing’s disease
clinical recovery, 21
imaging results in, 19
patient presenting with, 18
pituitary adenomas and, 95–96

D
Dacey, Ralph, 66
Data
categories of, 54
repositories of, 5
Data analysis
practice-based learning and, 4
research design and, 28–29
Data collection
performance improvement and, 4
research design and, 28–29
DBS. see deep brain stimulation (DBS)
Decision making
clinical creativity and, 50
paternalism in, 34
problem-based, 52
process of, 52
Declaration of Helsinki, 34
Deep brain stimulation (DBS), 9
closed-loop interfaces, 12–13
device-centric advancements, 10–11
electrical field surrounding, 11
interpreting cerebral activity, 12–13
lead geometry, current steering and, 11
optimization of, 9–12
reduction of infections, 10–11
state-of-the-art technology, 9–10
targeting advances, 11–12
volume of tissue activated, 11
Department of Health and Human Services, 46–47
Depression, DBS for, 9
DICER, siRNA processing by, 107
Differential diagnoses, concept of, 54
Digital subtraction angiography, 41
Diphenylhydrantoin, 74
Discoveries, implementation of, 50
Donovan, William, 89
Doppler probes, 120, 120
Drosohila, studies in neuromodulation using, 14
Dystonia, DBS for, 9

E
Eden, Sonia, 68
Education. see also continuing medical education
goals of, 3
residency redesign, 66–69
teaching of clinical wisdom, 51–52
Effect size, instructional methodology studies, 60
Einstein, Albert, 49, 51
Electrophysical analysis, BAC—transgenic hESC cells, 127
Embryonic stem cells. see human embryonic stem cells (hESCs)
Epidermal growth factor receptor (EGFR), 102
Equipoise, concept of, 35–36, 37
“Era of Professional Accountability,” 46
Essential tremor, DBS for, 9
Estrogens, suppression of IGF-1, 22
Ethics issues
in clinical research, 34
for neurosurgical clinical trials, 36
principles of clinical research, 35t
randomization of patients, 54
Evidence. see also medical evidence
levels of, 55t
tyranny of, 51
Evidence-based instruction, 59, 60–65
Evidence-based medicine
barriers to adoption of, 55
collaborative, 7
decision making and, 51
incorporation of experience into, 54–56
medical evidence for, 24–33
trends toward, 5
Expert opinions, as evidence, 24
External validity, of RCTs, 29–30

F
Facts, knowledge and, 59
Fiberoptic probes, 12
Fiducials
cost of, 80–83
overall accuracy of registration (OAR), 80
skin, 93
Financial biases, 51
Fixed-effects methods, meta-analyses, 29
Flemming, Alexander, 49–50, 50
Florey, Howard, 50
Flow cytometry
cell culture study, 108–110
hESC-derived motor neurons, 125–126
Fluorescence detection endoscopes, 93
Fluorescence-guided resection (FGR)
ALA-induced, 93–97
completeness of resection using, 96
specificity of, 96
Fluorescence image-guided surgery (FIGS), 93–97
Foramen ovale
anulla penetrating, 75, 75
percutaneous injection through, 73
Forgive and Remember (Bosk), 35
FoxP3
immunohistochemical staining, 99, 99
prognostic significance of, 98, 100–102, 101t, 101t
Treg cell expression of
inhibition of antitumor immunity by, 98
tumor grade and, 100t
Frameless stereotaxy. see also neuronavigation; Stealth frameless stereotactic system
benefits of, 20–21
targeting improvements and, 11, 12
Frequentist trial designs, 38

G
Gabapentin, 74
Gallium nitride lasers, 93
γ-aminobutyric acid (GABA), 13
Gasserian ganglion, injection with alcohol, 73
Geer, Carol, 68
Generalizability, of RCTs, 29–30
Generative processing, fostering of, 64–65, 65t
Glia fibrillary acidic protein, 15
Glioblastoma multiformae
AL-A-induced fluorescence, 95, 95
cell culture lines, 107–108
fluorescence under blue light, 94
immunohistochemical staining, 99
prognosis, 96, 100, 101
proteasome inhibition for, 107–118, 114f
under standard light, 94
Treg/CD4 T cell ratio in peripheral blood, 98
Glioma tissue microarrays, 99t
Gliomas
AL-A-induced fluorescence, 95
immunohistochemical staining, 99
role of Tregs, 98–106
Tregs and patient survival, 100–102
Gliosarcomas, IHC staining, 99
Globus pallidus
internal segment of
deep brain stimulation, 9
local field potential synchrony, 13
Glutamatergic acid decarboxylase, 13
Golden Rule, 53, 53
Gorelick, Judy, 68
Government Accountability Office, 70, 71
GRADE Working Group, 30
Green fluorescent protein (GFP)
BAC expressing, 125–130
motor neuron-specific expression of, 129
Growth hormone (GH) production, 21

H
Haines, Stephen, 54
Hamamatsu Orca-ER CCD camera, 110
Hb9 transcription factor, 125, 129, 130
Headaches, cluster-type, DBS for, 9
Health care, social framework of, 71
Health insurance, costs of, 70
Health policy, 71
Healthcare, costs of, 70
Heterogeneity, measures of, 29
Historical controls, 26
Honesty, wisdom and, 50
Hook effect, 22
Hormone replacement therapy (HRT) studies, 26
Hospital Quality Alliance (HQA), 47
Hospitalization, cost of, 70
Human cognitive structure, 7
Human embryonic stem cells (hESCs)
culture of, 125
directed development of, 130–131
motor neurons derived from, 125–132
potential of, 125
Human subjects
concept of equipoise, 35–36
protection of, 35
Hyperthyroidism, primary, 18–19
Hypocortisolism, presentation, 19
Hypophysitis, treatment of, 18
Hypothyroidism
clinical, screening for, 18
primary, 18
pseudotumor, 18

I
Ideas, generation of, 50
Immunofluorescence studies, 127
Infections, postoperative
DBS-related, 10–11
Inferior petrosal sinus sampling, 19
Inflammatory responses, CB2 receptor and, 85
Information literacy, 5
Informed consent, 35, 38
Innovation
clinical wisdom and, 49–50
fostering of, 50
process of, 50
Institute of Medicine (IOM), 46
Instruction
definition of, 58
evidence-based, 59
methods research, 59
objectives, 58–59
process of, 59
reducing extraneous processing, 61–63
science of, 58–60
Instrumental variables, 27
Insulin-like growth factor 1 (IGF-1), 21
suppression of, 21, 22
Integrating, process of, 58
Intellectual bias, 51
Intent-to-treat analyses, 28
Interleukin-2, 102
Interleukin-10, 102
Internal pulse generators (IPGs)
cranially-mounted, 10
for deep brain stimulation, 9–10
infraclavicular, 10
longevity of, 11
placement, 10
postoperative infections, 10–11
Intracranial lesions
identification using ALA, 93–97
localization using ALA, 93–97
resection using ALA, 93–97
Intraparenchymal cerebral hemorrhages, 44
Investigational devices, exemption studies, 51
Investigator bias, 51
Ionizing radiation
sensitivity screen, 108, 109
sensitization to, 111–114

J
Janus kinases/signal transducers and activator of transcription 3 (JAK/STAT3) pathway, 102
Joint Commission on the Accreditation of Healthcare Organizations (JCAHO), 46, 47
Justice, principle of, 34, 35t

K
Kerr-Jakoby, Ruth, 68
Kerrisoni punches, 20
Killian speculum, 19
Kintra DBS IPG, 11
Kir2.1 channel, 13
Knowledge
collective generation of, 6
components of, 3
definition of, 49
experience and, 53
explosion of, 3
gaps in, 3
instructional objectives, 58–59
kinds of, 59
medical, 3
Knowledge management, 2–8
Knowledge societies, 2–8
Kolb, David, 4, 4, 49, 52

L
Labor unions, 47
Lactacystin, cell culture studies, 108
Lanreotide (Somatuline Depot), 21
Leaning theory, tenets of, 2–3
Leapfrog Group, 46
Learners
active learning by, 57
adult, 3–4
clinicians as, 5
communities of, 5
empowerment of, 2
instruction centered on, 58
mentors for, 45
roles of, 57
Learning
definition of, 57
enlightened, 2–8
essential processing, 63–64
in a knowledge society, 2–8
meaningful, 59
outcomes, 59
performance improvement and, 3
practice-based, 4–5
principles of, 57–58
process of, 57–58
by rote, 59
science of, 57–65
self-directed, 3
support from learning programs, 4–5
systems
key initiatives, 7
role of teachers in, 2
Learning programs, barriers to, 6
Learning Sciences, function of, 2
Lehmann, Emily, 68
Lesioning, neuromodulation using, 9
Lesions, pituitary, 18
Levothyroxine replacement, 18
Licensure and Professional Standing, 45
Lifelong Learning and Self-assessment, 45–46
Light, neuromodulation by, 14
Lightning, formation of, 60, 61
Lindeman, Eduard, 7, 7
Live cell imaging, 110–111
Local field potential (LFP) synchrony, 13
Logical empiricism, 49
Long-term memory, 58
Lumbar disc herniation, 55

M
Magnetic resonance imaging (MRI)
arteriovenous malformations, 41
surgical outcomes, 42, 42t, 43
diagnostic, 41
imaging deep nuclei, 11
pituitary gland, 20
surgical planning and, 93
visibility of vitamin E capsules, 81
Maintenance of Certification (MOC), 5, 45–46
Malignant gliomas, classification, 26–27. see also gliomas
Mammosomatotrophic tumors, 21
Market pressures, forms of, 51
Matching, of controls, 26
Meckel’s cave, 76
Medical evidence
classification of, 24
clinical wisdom and, 51
definitions of, 24–33
hierarchy of, 24, 25t
moving to recommendations, 29–30
Medical liability insurance, 70
Medicare
impact on the federal budget, 70–71
Payment Advisory Commission, 70, 71
payment policies, 70
scheduled fee cuts, 70
trustees, 70
Medtronic 3387, 9
Medtronic 3389, 9
Memory, types of, 58
Meningiomas, ALA-induced fluorescence, 95
Mentors, learning experience and, 45
MER, electrode placement, 12
Meta-analyses
as evidence, 25
of individual patient data, 29
steps in, 28–29
Metacognition
clinical wisdom and, 53
definition, 3
skills needed for, 3
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 13
Methylprednisolone, for spinal cord injury, 84
Microelectrode targeting, intraoperative, 11
Micropore adhesive tape, 81
Microscope photodiagnosis system (PDS), 93
Milk fat, for fiducials, 80, 83
Miller, Carol, 68
Minimally conscious state, DBS for, 9
Mixed oligoastrocytomas, IHC staining, 99
Modality principle, essential processing, 63t, 64, 64
table
Molière, 52
Motor neurons
differentiation of, 125–126
electrophysical analysis, 128
enrichment via cell sorting, 128
GFP expression, 129
human stem cell-derived, 125–132, 126, 128
postsort culture of, 126
spinal, 131
transcriptome analysis, 128–130, 131
MTT Viability Assay Kit, 108
Multimedia learning
animation on lightning formation, 60, 61, 61
cognitive theory of, 58, 58
evidence-based principles of, 60–65
fostering generative processing, 64–65
lesson design, 60
in neurosurgery education, 57
role of technology in, 58
seductive details, 61
Multimedia principle, generative processing and, 64–65, 65t
Multiple myelomas, ALA-induced fluorescence, 95
Multivariate analysis, controls, 26
Muraszko, Karin, 68
National Acute Spinal Cord Injury Study, 55
National Board of Medical Examiners, 45
National Committee on Quality Assurance, 46, 47
National Quality Forum, 47
Neomycin/polymyxin solution, prophylactic, 10
Neuromodulation
advances in, 9–17
biologics-based, 13–15
optogenetics, 14–15
Neuroradiology. see also frameless stereotaxy; Stealth frameless stereotactic system
fiducials, 80–83
Neuropace responsive neurostimulator, 10
Neuroprotection, CB receptors and, 84–92
Neurosurgeons, advocacy role of, 71
Neurosurgery
definition of quality in, 45–48
economic forces against, 70–71
medical education in, 57
medical school experience, 45
postgraduate years, 66
residency experience, 45
residency redesign, 66–69
Nietzsche, Friedrich, 50–51, 52
Nikon Plan Fluor objective, 110
Nikon TE2000E PFS microscope, 110
Noninferiority design, 38–39
NpHR channel, 15
Obesity, DBS for, 9
Observational studies
selection of control populations, 26
unpredictability paradox, 27
Observations, as evidence, 25
Obsessive-compulsive disorder, DBS for, 9
Occipital electrodes
migration of, 119
positioning of, 121
Occipital nerve stimulation
complications, 122
electrodes, 119, 121
intraoperative photographs, 121
for occipital neuralgia, 119–124
operative technique, 119, 120
outcomes, 121–122, 123t
patient demographics, 122t
patient positioning, 120
patient selection, 119
postoperative skull x-ray, 121
stimulation parameters, 122t
Occipital neuralgia (ON)
definition of, 119
occipital nerve stimulation for, 119–124
patient demographics, 122t
Octreotide (Sandostatin LAR), 21
Oligodendromas, IHC staining, 99
Operating room setups, TGN treatment, 74
Opportunity, clinical wisdom and, 49–50
Optic chiasm, elevation of, 20
Optical biopsy system (OBS), 93–94, 94
Organizing, process of, 58
Osler, William, 2, 6, 7, 50
Outcomes, optimization of, 51
Overall accuracy of registration (OAR), 80
Oxcarbazepine, for trigeminal neuralgia, 74

P
P53 status, 107, 112–113, 115
Paige, Satchel, 53
Parasellar lesions, 19t, 22
Parkinson’s disease, DBS for, 9, 13
Pasteur, Louis, 49
Paternalism, decision making and, 34
PathFinder surgical robotic system, 93
Patient-centric approaches, 51
Patient positioning, for TGN treatment, 75
Patients
autonomy of, 34
selection of
biases, 51
for occipital nerve stimulation, 119
for trigeminal balloon compression, 74
sham surgeries, 35
Pay-for-performance bonuses, 70
Pegvisomant (Somavert), 21
PEP-3-KLH/CDX-110, 103, 104
Percutaneous balloon compression, for TGN, 73–79
outcomes, 77
postoperative management, 77
recurrence rates, 77
 technique, 74–77
Percutaneous occipital electrodes, migration of, 119
Performance improvement. see also quality
practice-based learning and, 4
self-directed learning and, 3
Personalization principle, 65, 65t
Petrosal sinus sampling, 21
Petrous bone, 76
Photo bleaching, of PpIX fluorescence, 96
Physician–patient communications, 34, 35
Physicians, decision making by, 34
Physician’s Consortium for Performance Improvement Program
(AMA), 46
Pituitary adenomas
age at diagnosis, 18
ALA-induced fluorescence, 95
incidence of, 18
microadenomas, 19
outcomes, 21
resectioning, 19
prolactin-secreting, 22
race and, 18
Pituitary-adrenal axis, assessment, 19
Pituitary gland
enlarged, 20
lesions
parasellar, 19t
presentation of, 18
sellar, 19t
microadenomas, 19
treatment for disorders of, 18–22
Placebo effects, 35
Polymerase chain reactions, 127, 130
Popp, John, 66
Porras, Jerry I., 51
Potassium ion channels, Kir2.1, 13
Practice-based data, repositories of, 5
Practice-based learning, 4
activities involved in, 4
application of, 4–5
the knowledge society and, 6
Practice Performance Assessment, 46
Prednisone, for hypophysitis, 18
Preproenkephalin gene, 13
Pressure monitors, digital, 75
Pretraining principle, essential processing and, 63, 63t, 64
Primary central lymphoma, ALA-induced fluorescence, 95
Procedures, knowledge and, 59
Professional interactions, learning through, 5
Prognostic factors
meta-analyses and, 25
multivariate analysis, 26
Prolactin, measurement of, 22
Prolactinomas, treatment, 22
Propensity scores, 27
Proteasome inhibitors
function of, 107
for GBM, 107–118, 114f
Proteasomes, composition of, 107
Protophoryin-IX (PpIX), 93–97
photo bleaching of, 96
PSMA (prosome, macropain subunit, alpha type I) silencing, 111–114
Public opinion, on healthcare quality, 47
Publication bias, 26, 29, 51

Q
QIAGEN DNA repair siRNA library, 111
Quality
“beholders” of, 46–47
in medicine, 45
in neurosurgical practice, 45–48
Quality Alliance Steering Committee, 47

R
Radiation therapy
in acromegaly, 21
for GBM, 107
Radiation Therapy Oncology Group, 26–27
Radiofrequency (RF) antennae, 9
Radiofrequency (RF) generators, 73
Radionics, Inc., 73
Radiosurgery, for AVMs, 41

© 2009 The Congress of Neurological Surgeons
Random-effects method, meta-analyses, 29
Randomization, instructional methodology studies, 59
Randomized controlled trials (RCTs)
  blinding, 27
  clinical problems addressed by, 54
  completeness of follow-up, 27–28
  ethics of randomization, 54
  as evidence, 24
  external validity of, 29–30
  generalizability of, 29–30
  phase III, 27–28
  surgical
    special problems with, 28
    timing of, 28
  treatment allocation, concealment of, 27
Recommendations, from evidence to, 29–30
Recursive Partitioning Analysis classification, 26–27
Redundancy principle, 61t, 62
Reflex hypertension, trigeminal nerve compression and, 74
Regulatory bodies, data collection by, 4
Regulatory T cells (Tregs)
  FoxP3 positive, 98
  frequency in gliomas, 98–100
  incidence in gliomas, 98–100
  inhibition of antitumor immunity by, 98
  inhibition with STAT3 blockade, 102–105
  role in human glioma patients, 98–106
Research designs
  adaptive design, 38
  with animal models, 85–87
  bayesian design, 38
  blinding in, 27
  completeness of follow-up, 27–28
  control populations, 26
  crossover designs, 28
  ethics issues, 34
  frequentist design, 38
  historical basis of ethics in, 34–35
  instructional method studies, 59
  meta-analyses, 28–29
  noninferiority design, 38
  observational case series, 25–27
  patient numbers needed for, 37, 38
  for phase III trials, 38t
  prospective, 38t
  protection of human subjects, 35
  reduction of bias in, 27
  spinal cord injury study, 85–87
  systematic reviews, 28–29
  target populations, 37
  treatment allocation concealment, 27
  Zelen design, 37–38
Residency
  core curricula, 66–67
  postgraduate years, 66
  redesign of, 66–69
  six year format, 66
Residency Review Committee, 45, 66
Restore IPG option, 11
RestoreUltra spinal cord stimulator, 11
Retinoic acid, 125–126, 128
Rhodopsin gene, 14
Rifampin/minocycline, equipment impregnated with, 11
RISC (RNA-inducing silencing complex), 107
Risk stratification scores, 26–27
Rogers, Carl, 3, 3
Rota Rod testing, of mice, 86, 88, 89
Sackett, David, 51
SANS Lifelong Learning, 6
SANS (Self-Assessment in Neurological Surgery), 46
Segmenting principle, in essential processing, 63–64, 63t
Selecting, process of, 58
Selection bias, 25–26, 51
Self-assessment, practice-based learning and, 4
Self-Assessment in Neurological Surgery, 5
Self-directed learning, 3
Self-reflection, wisdom and, 52
Sella
  lesions, 19t
  opening of, 20
  reconstruction of, 20
  visualization of, 19
Sensory memory, 58
Sham surgeries, 35
Signaling principle, extraneous processing and, 61t, 62
Small interference RNA (siRNA)
  proteasome inhibition using, 107–118
  screening use of, 108, 111–114, 112
Society of Neurological Surgeons, 66, 67, 70
Soleta IPG, 10
Soleta unilateral DBS IPG, 11
Somatomedin C. see insulin-like growth factor 1 (IGF-1)
Somatostatin analogues, 21
Sonic hedgehog, cell culture using, 126, 128
Spasme cinique. see trigeminal neuralgia
Spatial contiguity principle, extraneous processing and, 61t,
  62–63, 63
Spetzler-Martin classification of AVMs, 40
  distribution of patients based on, 42t
  outcomes and, 41–44
  surgical results, 42, 42t, 43t, 44t
  treatment strategies and, 41t
Spinal cord injury (SCI)
  clinical trial, 55
  costs of, 84
  iatrogenic, 0
  incidence of, 84
  neuroprotective agents, 89–91
  research designs, 85–87
Spine Patient Outcomes Research Trial, 55
SR141716, 85
STAT3 (signal transducer and activator of transcription 3), 102–105
Statistical inference, principle of, 38
Stealth frameless stereotactic system, 20, 21. see also neuronavigation
StealthStation, 80–83, 93
Steroids, high-dose, 84
Strahle, Jennifer, 68
Strategies, knowledge and, 59
The Student Life (Osler), 6
Substantia nigra, neuronal death in, 13
Subthalamic nucleus (STN)
  deep brain stimulation, 9
  local field potential synchrony, 13
  targeting advances, 12
Supratentorial arteriovenous malformations, 40–44
Synaptic transmission, modification of, 13–14
Synaptobrevin, 13
T cells. see also regulatory T cells (Tregs)
  CD4, proliferation of, 98
  CD8, in gliomas, 99
  cytotoxic/regulatory ratio, 101
  immunohistochemical staining, 99
  WHO grade tumors and, 100
Tasks, knowledge and proficiency for, 59
Technology
  costs of care and, 70
  instruction centered on, 58
  knowledge management and, 2
Temozolomide (TMZ)
  cell culture studies, 108
  cell fate after Velcade and, 113–114
  effect on U87 cell xenografts, 114, 115
  efficacy in GBM, 107
  growth arrest study, 110
  inhibition of Treg trafficking, 102
  p53 status and, 112–113
  sensitivity screen, 108, 109
  sensitization by proteasome inhibition, 112–113, 113, 116
  sensitization to, 111–114, 114f
Temporal contiguity principle, extraneous processing and, 61t, 63
Thermocoagulation, 73
Third-party payers, data collection by, 4
Thyroid pseudotumor (hyperplasia), 18
Thyroid-stimulating hormone (TSH), 18
Thyroxe (T4), in primary hypothyroidism, 18
Tic douloureux. see trigeminal neuralgia
Tissue glue, use of, 20
To Err Is Human (IOM), 46
Tourette’s syndrome, DBS for, 9
Transcriptome analysis, 127, 131
Transforaminal balloon, 73
Transgenes, in neuromodulation, 13–14
Transnasal approach, in microadenomas, 19–20
Transsphenoidal approach, extended, 22
Treatments
  allocation in research studies, 27
  effectiveness studies, 30
  efficacy of, 30
  evidence-based medicine and, 54
  Tregs. see regulatory T cells
  Trigeminal depressor responses, 74
  Trigeminal neuralgia (TGN)
    operating room setup, 74
    percutaneous balloon compression for, 73–79
    postoperative management, 77
    treatment of, 74
    trigger points, 73
  Trigeminal roots, biopsy of, 73
  Tumors
    Treg cells in, 98
    WHO grade, 100
    Tuskegee study, 34

T
  T cells. see also regulatory T cells (Tregs)
  CD4, proliferation of, 98
  CD8, in gliomas, 99
  cytotoxic/regulatory ratio, 101
  immunohistochemical staining, 99
  WHO grade tumors and, 100
T
  T cells. see also regulatory T cells (Tregs)
  CD4, proliferation of, 98
  CD8, in gliomas, 99
  cytotoxic/regulatory ratio, 101
  immunohistochemical staining, 99
  WHO grade tumors and, 100
T
  T cells. see also regulatory T cells (Tregs)
  CD4, proliferation of, 98
  CD8, in gliomas, 99
  cytotoxic/regulatory ratio, 101
  immunohistochemical staining, 99
  WHO grade tumors and, 100
Tasks, knowledge and proficiency for, 59
Technology
  costs of care and, 70
  instruction centered on, 58
  knowledge management and, 2
Temozolomide (TMZ)
  cell culture studies, 108
  cell fate after Velcade and, 113–114
  effect on U87 cell xenografts, 114, 115
  efficacy in GBM, 107
  growth arrest study, 110
  inhibition of Treg trafficking, 102
  p53 status and, 112–113
  sensitivity screen, 108, 109
  sensitization by proteasome inhibition, 112–113, 113, 116
  sensitization to, 111–114, 114f
Temporal contiguity principle, extraneous processing and, 61t, 63
Thermocoagulation, 73
Third-party payers, data collection by, 4
Thyroid pseudotumor (hyperplasia), 18
Thyroid-stimulating hormone (TSH), 18
Thyroxe (T4), in primary hypothyroidism, 18
Tic douloureux. see trigeminal neuralgia
Tissue glue, use of, 20
To Err Is Human (IOM), 46
Tourette’s syndrome, DBS for, 9
Transcriptome analysis, 127, 131
Transforaminal balloon, 73
Transgenes, in neuromodulation, 13–14
Transnasal approach, in microadenomas, 19–20
Transsphenoidal approach, extended, 22
Treatments
  allocation in research studies, 27
  effectiveness studies, 30
  efficacy of, 30
  evidence-based medicine and, 54
  Tregs. see regulatory T cells
  Trigeminal depressor responses, 74
  Trigeminal neuralgia (TGN)
    operating room setup, 74
    percutaneous balloon compression for, 73–79
    postoperative management, 77
    treatment of, 74
    trigger points, 73
  Trigeminal roots, biopsy of, 73
  Tumors
    Treg cells in, 98
    WHO grade, 100
    Tuskegee study, 34

U
U87MG cell studies, 107–114
Unpredictability paradox, 27

V
Validity, of RCTs, 29–30
Velcade (bortezomib)
  cell culture studies, 108
  cell fate after TMZ and, 113–114
  delayed treatment with, 113–114
  effect on U87 cell xenografts, 114, 115
  growth arrest study, 110
  sensitizing effect of, 116–117
  TMZ treatment with, 113
  tumoricidal activity, 111
Venes, Joan, 68
Ventral intermediate nucleus of the thalamus, DBS, 9
Ventricular drains, antibiotic-impregnated, 11
Vitamin E capsules, 80, 80–82, 81, 82
Vogelbaum, M.A., 37–39
Voltaire, 52
Volume of tissue activated (VTA), 11

W
Web 2.0 movement, 5
Weiss, Kevin, 46
Wiki, learning and, 5
WIN 55,212–2, 85
Wisdom, the concept of, 49–53
Women, in neurosurgery, 68, 68
Working memory, 58
World Medical Association, 34
Worst-case sensitivity analyses, 28
WP1066, 102, 103

Y
Yang, Lynda, 68

Z
Zelen design, for research, 37–38